[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2459553T3 - Furazanobenzimidazole jako proleki do leczenia chorób nowotworowych lub autoimmunizacyjnych - Google Patents

Furazanobenzimidazole jako proleki do leczenia chorób nowotworowych lub autoimmunizacyjnych

Info

Publication number
PL2459553T3
PL2459553T3 PL10740196T PL10740196T PL2459553T3 PL 2459553 T3 PL2459553 T3 PL 2459553T3 PL 10740196 T PL10740196 T PL 10740196T PL 10740196 T PL10740196 T PL 10740196T PL 2459553 T3 PL2459553 T3 PL 2459553T3
Authority
PL
Poland
Prior art keywords
furazanobenzimidazoles
prodrugs
autoimmune diseases
treat neoplastic
neoplastic
Prior art date
Application number
PL10740196T
Other languages
English (en)
Inventor
Jens Pohlmann
Felix Bachmann
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Publication of PL2459553T3 publication Critical patent/PL2459553T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL10740196T 2009-07-27 2010-07-26 Furazanobenzimidazole jako proleki do leczenia chorób nowotworowych lub autoimmunizacyjnych PL2459553T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09166469 2009-07-27
PCT/EP2010/060803 WO2011012577A1 (en) 2009-07-27 2010-07-26 Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases
EP10740196.0A EP2459553B1 (en) 2009-07-27 2010-07-26 Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases

Publications (1)

Publication Number Publication Date
PL2459553T3 true PL2459553T3 (pl) 2015-03-31

Family

ID=41226617

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10740196T PL2459553T3 (pl) 2009-07-27 2010-07-26 Furazanobenzimidazole jako proleki do leczenia chorób nowotworowych lub autoimmunizacyjnych

Country Status (25)

Country Link
US (1) US8802858B2 (pl)
EP (1) EP2459553B1 (pl)
JP (1) JP5576485B2 (pl)
KR (1) KR101758400B1 (pl)
CN (1) CN102471329B (pl)
AU (1) AU2010277688B2 (pl)
BR (1) BR112012001817B8 (pl)
CA (1) CA2767875C (pl)
CY (1) CY1115809T1 (pl)
DK (1) DK2459553T3 (pl)
EA (1) EA021380B1 (pl)
ES (1) ES2524119T3 (pl)
HK (1) HK1166316A1 (pl)
HR (1) HRP20141120T1 (pl)
IL (1) IL217195A (pl)
MX (1) MX336240B (pl)
NZ (1) NZ597376A (pl)
PL (1) PL2459553T3 (pl)
PT (1) PT2459553E (pl)
RS (1) RS53679B1 (pl)
SI (1) SI2459553T1 (pl)
TW (1) TWI457337B (pl)
UA (1) UA106763C2 (pl)
WO (1) WO2011012577A1 (pl)
ZA (1) ZA201200228B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3142744A1 (en) 2011-01-21 2012-07-26 Basilea Pharmaceutica Ag Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles
CA2822540A1 (en) * 2011-01-21 2012-07-26 Basilea Pharmaceutica Ag Stathmin as a biomarker for furazanobenzimidazoles
HUE032643T2 (en) 2011-01-21 2017-10-30 Basilea Pharmaceutica Ag Use of BUBR1 as a biomarker for response to furazanobenzimidazoles
JP6295081B2 (ja) 2011-02-24 2018-03-14 バジリア ファルマスーチカ アーゲーBasilea Pharmaceutica AG フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのアセチル化チューブリンの使用
WO2012130887A1 (en) * 2011-03-29 2012-10-04 Basilea Pharmaceutica Ag Use of phospho-akt as a biomarker of drug response
US9558575B2 (en) 2012-02-28 2017-01-31 Blackberry Limited Methods and devices for selecting objects in images
ITRM20130248A1 (it) * 2013-04-24 2014-10-25 Medivis S R L Formulazioni di riboflavina per il cross-linking transepiteliale.
WO2015173341A1 (en) * 2014-05-13 2015-11-19 Basilea Pharmaceutica Ag Dosage principle for anti-cancer furazanylbenzimidazoles
EP3365680A1 (en) * 2015-10-22 2018-08-29 Basilea Pharmaceutica International AG Use of eb1 as a biomarker of drug response
WO2018193385A1 (en) * 2017-04-20 2018-10-25 Pi Industries Ltd. Novel phenylamine compounds
JP7191298B2 (ja) 2017-04-26 2022-12-19 バジリア・ファルマスーチカ・インターナショナル・アーゲー,アルシュヴィル フラザノベンズイミダゾール類及びその結晶形の調製方法
WO2018210868A1 (en) 2017-05-16 2018-11-22 Basilea Pharmaceutica International AG Novel dosage principle for drugs useful for treating neoplastic diseases
WO2019097073A1 (en) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
EP3853224A1 (en) 2018-09-20 2021-07-28 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2021048135A1 (en) 2019-09-09 2021-03-18 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
CN111454254B (zh) * 2020-04-26 2023-06-02 云白药征武科技(上海)有限公司 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用
CN111423429A (zh) * 2020-05-19 2020-07-17 江西科技师范大学 苯并咪唑联呋咱类系列化合物及其合成方法
WO2022053549A1 (en) 2020-09-10 2022-03-17 Basilea Pharmaceutica International AG Use of c-myc as a biomarker of drug response

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
MXPA04007697A (es) * 2002-02-06 2004-11-10 Vertex Pharma Compuestos de heteroarilo utiles como inhibidores de gsk-3.
EP1636215B1 (en) * 2003-05-23 2008-01-23 Basilea Pharmaceutica AG Furazanobenzimidazoles
US20070167505A1 (en) * 2004-02-11 2007-07-19 Basilea Pharmaceutica Ag Substituted benzimidazoles and their use for inducing apoptosis

Also Published As

Publication number Publication date
IL217195A0 (en) 2012-02-29
ES2524119T3 (es) 2014-12-04
EA021380B1 (ru) 2015-06-30
MX336240B (es) 2016-01-13
ZA201200228B (en) 2012-09-26
MX2012000611A (es) 2012-01-27
US20120264792A1 (en) 2012-10-18
CY1115809T1 (el) 2017-01-25
TWI457337B (zh) 2014-10-21
CN102471329A (zh) 2012-05-23
KR20120055571A (ko) 2012-05-31
CN102471329B (zh) 2014-11-05
WO2011012577A1 (en) 2011-02-03
BR112012001817B8 (pt) 2021-05-25
DK2459553T3 (da) 2014-11-03
SI2459553T1 (sl) 2015-01-30
EP2459553A1 (en) 2012-06-06
AU2010277688A1 (en) 2012-02-09
TW201107318A (en) 2011-03-01
JP5576485B2 (ja) 2014-08-20
HK1166316A1 (en) 2012-10-26
IL217195A (en) 2014-03-31
JP2013500304A (ja) 2013-01-07
KR101758400B1 (ko) 2017-07-14
UA106763C2 (uk) 2014-10-10
BR112012001817B1 (pt) 2020-09-29
RS53679B1 (en) 2015-04-30
AU2010277688B2 (en) 2013-12-05
HRP20141120T1 (hr) 2015-01-30
CA2767875A1 (en) 2011-02-03
BR112012001817A2 (pt) 2016-03-15
PT2459553E (pt) 2014-11-24
US8802858B2 (en) 2014-08-12
EA201200189A1 (ru) 2012-08-30
NZ597376A (en) 2014-01-31
EP2459553B1 (en) 2014-10-01
CA2767875C (en) 2016-03-15

Similar Documents

Publication Publication Date Title
HK1166316A1 (en) Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases
HK1182387A1 (en) 1-substituted-carba-nucleoside prodrugs for antiviral treatment 1--carba-
IL221055A0 (en) Water treatment process
HK1182688A1 (zh) 水處理工藝
IL218683A0 (en) Prodrugs of guanfacine
EP2493820A4 (en) WATER TREATMENT
IL275350B (en) Treatment of neoplastic diseases
AP3665A (en) Water treatment
IL213673A0 (en) Spiroindolinone derivative prodrugs
GB0904427D0 (en) Treatment of diseases related to hyperactivity of the complement system
ZA201300320B (en) Purification process
IL214598A0 (en) Water wheel
SI2315743T1 (sl) Postopek čiščenja dialkil sulfidov
GB0900599D0 (en) Treatment
IL213919A0 (en) Methods to treat cancer
IL222610A0 (en) Multifunctional locomotor
GB0909963D0 (en) Attachment to inline skates
GB201001521D0 (en) Treatment
GB0913968D0 (en) Treatment
GB201006678D0 (en) Inline drop-net
EP2632259A4 (en) HYPERSULATED DISACCHARIDES FOR THE TREATMENT OF ELASTASE-MEDIATED DISEASES
GB0911469D0 (en) Compounds to treat neurodegenerative disease
GB0905127D0 (en) Novel prodrugs
GB0915307D0 (en) Pond units
GB0904178D0 (en) General cure to diseases idea 3